Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 déc. 2024 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
27 nov. 2024 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following December investor conferences: ...
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
12 nov. 2024 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare...
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
05 nov. 2024 07h05 HE
|
Apellis Pharmaceuticals, Inc.
Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue...
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
26 oct. 2024 14h00 HE
|
Apellis Pharmaceuticals, Inc.
Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints favored treatment with pegcetacoplan,...
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
22 oct. 2024 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third...
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
16 oct. 2024 07h00 HE
|
Apellis Pharmaceuticals, Inc.
Company to host a webinar on the detailed VALIANT results at 12:30 p.m. PT on Saturday, October 26 WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS)...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 oct. 2024 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant...
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
25 sept. 2024 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the UBS Virtual Ophthalmology Day on...
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
20 sept. 2024 05h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...